Achilles Therapeutics Plc EBIT

Achilles Therapeutics Plc (ACHL) currently reports a EBIT of $-72M as of September 2024. That compares with $-79M in the prior-year period — up 8.7% year over year. That is below the Healthcare sector average of $22B. Use the charts on this page to explore Achilles Therapeutics Plc's EBIT history and peer comparisons.

Achilles Therapeutics Plc's EBIT increased from $-79M to $-72M — a 8.7% year-over-year increase (period ending September 2024). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Achilles Therapeutics Plc's EBIT of $-72M is lower than the Healthcare sector average of $22B. That is roughly 100.3% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Achilles Therapeutics Plc reported $-72M in EBIT as of September 2024. That compares with $-79M in the prior-year period — up 8.7% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current EBIT of $-72M, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $22B. From there, open related valuation or income-statement pages for Achilles Therapeutics Plc, and consider following ACHL for alerts when major investors trade the stock.